Maia Biotechnology Announced Updates On Preliminary Survival Data In The Part A Safety Lead-in Of Its Ongoing THIO-101 Phase 2 Trial Evaluating THIO In Sequential Combination With Cemiplimab In Advanced Non-small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Maia Biotechnology has announced preliminary survival data from the Part A safety lead-in of its ongoing THIO-101 Phase 2 trial. The trial is evaluating THIO in sequential combination with Cemiplimab in advanced non-small cell lung cancer. The first two patients dosed with THIO have shown no documented progression for 12.2 and 11.5 months, and no new anti-cancer treatment 10.2 and 8.5 months after concluding treatment with THIO.
July 10, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maia Biotechnology's ongoing THIO-101 Phase 2 trial shows promising preliminary results, potentially boosting the company's stock in the short term.
The positive preliminary results from Maia Biotechnology's THIO-101 Phase 2 trial could lead to increased investor confidence in the company's potential, possibly driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100